Clinical trials: Tubal Patency
Contraception
Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
This study is designed to assess post-procedural outcomes for women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization, including: Pelvic and/or lower abdominal pain Abnormal…
- Trial name
- NCT03127722
- Testing
- Blood draw, ESSURE (BAY1454032), Laparoscopic tubal sterilization
- Where
- 57 sites in United States
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Bayer
Infertility
A Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility
The study tested the hypothesis that a pertubation with a lidocain solution will enhance pregnancy rate.
- Trial name
- NCT00449449
- Testing
- Pertubation with Lidocain Solution
- Where
- Sweden
- Volunteers
- 330 people
- Sponsor
- Isifer AB
Fallopian Tube Patency Tests
Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSG
Multi-center prospective comparison of fallopian tubal patency determination and uterine evaluation interventions using legally marketed devices for their intended purposes, and using each subject as their own control.
- Trial name
- NCT01053052
- Testing
- Sonography with FemVue, and HSG
- Volunteers
- healthy volunteers welcome
- Sponsor
- Femasys Inc.
Ovarian Cancer
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients. Immunotherapy causes the body's defenses to react against cancer cells.
- Trial name
- NCT00086632
- Testing
- oregovomab
- Volunteers
- 40 people
- Sponsor
- Unither Pharmaceuticals
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche